This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Meningococcal Vaccines Market

Market Insights on Meningococcal Vaccines covering sales outlook, demand forecast & up-to-date key trends

Meningococcal Vaccines Market by Product, Age Group, Distribution Channel & Region - Forecast 2022 – 2032

Meningococcal Vaccines Market Outlook (2022-2032)

[312 Pages Report] Global meningococcal vaccines market is set to expand at a 8.6% CAGR over the forecast period, reaching US$ 3.4 Bn in 2022. As per Future Market Insights (FMI), in terms of revenue, conjugate vaccines segment dominated the market with 62.6% revenue share in 2021.

Data Points

Market Insights

Meningococcal Vaccines Market Base Year Value (2021)

US$ 3.1 Bn

Estimated Market Size (2022)

US$ 3.4 Bn

Projected Market Valuation (2032)

US$ 7.7 Bn

Value-based CAGR (2022-2032)

8.6%

Market Share of Top 5 Countries

65.9%

Rising prevalence of meningitis, growing demand for permanent cure of meningitis and private-public partnerships to provide funding for immunization programs are some factors that are expected to create opportunities for growth in the market.

Bacterial meningitis, also known as cerebrospinal meningitis, is more aggressive and can lead to permanent damage or death. Survivors of bacterial meningitis may suffer from long-term effects including hearing loss, brain damage, memory loss, learning difficulties, or even septicaemia.

Customize this Report

Let us know your requirement to get
100% FREE customization

How The Market Progressed Till June 2022?

Particulars

Details

H1, 2021

9.20%

H1, 2022 Projected

8.65%

H1, 2022 Outlook

8.15%

BPS Change - H1, 2022 (O) – H1, 2022 (P)

(-) 50 ↓

BPS Change – H1, 2022 (O) – H1, 2021

(-) 105 ↓

Comparative and review analysis of market dynamics for the meningococcal vaccines market by Future Market Insights revealed that H1-2022 outlook period in comparison to H1-2022 will project a negative growth in terms of Basis Point Share by 50 BPS. However, In H1-2022, the market growth rate of meningococcal vaccines is expected to fall by nearly 105 basis point share (BPS), as per FMI analysis.

A cost-effective vaccine would ideally only need a limited number of doses, be safe for infants, cover most of the pathogenic serogroups, be economically accessible, and offer lifetime immunity. Unfortunately, none of the vaccinations that are currently on the market satisfy these requirements.

Meningococcal polysaccharide vaccines (MPSV) and meningococcal polysaccharide-protein conjugated vaccines (MCV) are currently the only vaccinations for invasive meningococcal disease. MPSV have a number of drawbacks that make the adoption of MCV more advantageous.

First off, due to their low immunogenicity and high disease burden, MPSV are ineffective in younger children (less than 2 years), who have the highest incidence of disease.

Second, they are unable to give long-term immunity since, according to new evidence from a Cochrane review, immunity after the first year of immunisation is not well established. These disadvantages present a restraint towards the market values for meningococcal vaccines, and hence the associated BPS values.

2017-2021 Meningococcal Vaccines Market Historic Outlook Vs 2022-2032 Forecast

The market value for meningococcal vaccines accounted for nearly 5.3% of the overall US$ 59 Bn global vaccines market in 2021.

Threat of pandemic meningitis outbreaks drive investment by government and manufacturers that will propel the demand for meningococcal vaccines in the forthcoming years. Meningococcal outbreak is a public health challenge, especially meningococcal meningitis. The disease is associated with high rate of mortality and long-term neurological defects among infants and children.

Majority of developing countries, including BRICS are taking steps to initiate the development and production of meningococcal vaccines. This is creating significant opportunities for multinational companies to invest in the vaccine production. For instance, ABIVAX Société Anonyme, a French biotechnology company, collaborated with Latin American meningococcal vaccine manufacturer Finlay institute of vaccines in 2014 to commercialize meningococcal vaccines.

Meningococcal vaccinations that are being included in national immunisation programmes will assure a long-term and inexpensive supply of vaccines for both the public and private sectors. For instance, in July, 2020 GSK Australia given Meningococcal B (MenB) vaccination for Aboriginal and Torres Strait Islander infants to the National Immunization Program (NIP).

With the help of global partners such as the World Health Organization (WHO) and the United Nations Children's Fund, vaccines are now being administered more quickly in low-income countries such as Africa. Expanding vaccine access in these underserved markets will augment the growth in the market.

According to the WHO vaccination coverage statistics, nearly 250 million Africans were immunised against meningococcal disease within six years of the vaccine's introduction. By the end of 2020, MenAfriVac will have vaccinated nearly 350 million people in 24 of the 26 nations in the meningitis belt.

The market is expected to expand at a 8.6% CAGR over the forecast period, offering an absolute $ opportunity of US$ 273.4 Mn.

Meningococcal Vaccines Market Download Report Brochure

What are the Key Opportunities for Meningococcal Vaccines Manufacturers?

Creating stable vaccine supply in emerging countries provides enormous growth opportunities for manufacturers of meningococcal vaccines. To ensure steady supply, manufacturers must look for high-quality manufacturing capacities to fulfil the unmet demand.

To respond effectively to emergency outbreaks of infectious diseases such as meningococcal disease, collaboration across many parties to develop and assess vaccines, as well as innovative supply and funding models, is becoming increasingly vital. As a result, firms have a great opportunity to enter this market to meet the unmet need for meningococcal vaccinations.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

What are the Factors Restraining Demand for Meningococcal Vaccines?

Factors restraining the demand for meningococcal vaccines include limited supply and dependency on few manufacturers. Manufacturer’s access is limited by country’s capacity to support immunization and unawareness among general population. There exists a vast difference in coverage of established and new vaccines, primarily due to low awareness among general population.

Demand of meningococcal vaccines mainly depends on disease outbreaks, funding decisions, adoption by NIP, regulatory scenarios, and competing vaccine introduction priorities. Besides this, manufacturers’ access to certain markets is restricted by the differential pricing strategies adopted by government of developing countries, which further restricts the penetration of newly approved/launched vaccine products.

Country-wise Insights

What is Driving the U.S. Meningococcal Vaccines Market?

“Surging Demand for Meningitis Vaccines in the U.S. will Augment Growth”

The U.S. leads the North America meningococcal vaccine market, accounting for about 94.0% of the total market share in 2021, and is estimated to show the high growth through the forecast period. Expansion in the healthcare sector, along with growing FDA approvals for vaccines and novel drugs in the U.S. will bode well for the market over the forecast period.

For example, the United States Food and Drug Administration (FDA) authorised PREVNAR 20, Pfizer's Pneumococcal 20-valent Conjugate Vaccine, for individuals aged 18 and above, in June 2021. In addition to this, the vaccine includes capsular polysaccharide conjugates for seven additional serotypes that cause invasive pneumococcal disease (IPD) and have been linked to high case fatality rates, antibiotic resistance, and/or meningitis.

Why is the U.K. Meningococcal Vaccines Market Considered Lucrative?

“Rising Prevalence of Meningococcal Disease in the U.K. Will Fuel Sales”

Demand in the U.K. is set to increase at a CAGR of 9.8% in the Europe meningococcal vaccines market during the forecast period. The coverage for immunization with meningococcal vaccines is as high as 90% in infants and 85% in children and adults in the country, which provides an opportunity for manufacturers to introduce their products in the market.

How is the China Meningococcal Vaccines Market Faring?

“Increasing Sales of Meningococcal B Vaccines in China Will Steer Growth”

China accounted for 50.7% of the East Asia meningococcal market share in 2021. High birth rate in China and rising prevalence of meningitis is underpinning the demand for meningococcal vaccines.

According to 2021 figures, the yearly incidence of meningococcal illness and carriage in China was 0.0017–0.0183 per 100,000 people in 2021. Incidence is highest in children under the age of one year, with a case fatality rate of 5.45 percent in 2021. Serogroup B has the highest rate of occurrence.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Category-wise Insights

Which Meningococcal Vaccines Product is Driving the Market?

“Sales of Conjugate Vaccines to Remain High”

Based on product type, the conjugate vaccines segment accounted for 62.6% of the total market share in 2021, owing to its advanced technological features and high adoption rates by end users. Weak antigen and vaccines are combined and linked to a strong antigen as a carrier. This can give strong immune response to weak antigen. This factor is expected to drive sales in the market over the forecast period.

Which is the Leading Age Group in the Meningococcal Vaccines Market?

“Demand for Meningococcal Vaccines Among Adolescents Will Gain Traction”

In terms of age group, sales in the adolescents & young adults segment are expected to grow at a CAGR of 7.6% over the assessment period. The segment accounted for about 30.5% of the total market share in 2021.

The metrics are valued as per the disease aggravation. This age group is more prone to meningococcal bacterial infection with life threating issues. In order to prevent the above mentioned factors, young adults have a higher adoption of meningococcal vaccines.

Which Distribution Channel Benefits the Most in the Meningococcal Vaccines Market?

“Adoption of Meningococcal Vaccines Across Public Health Agencies Will Gain Momentum”

By distribution channel, public health agencies held about 38.1% of the total market share in 2021. Public health agencies have a large foot fall for all kinds of vaccines. Also, companies are focusing on unique strategies for distribution of vaccines across public health agencies.

Competitive Landscape

Key players operating in the global meningococcal vaccines market are focusing on the development and launch with regulatory approvals for meningococcal vaccines.  Established players within the industry are focusing on mergers and acquisitions for improving their global presence. For instance:

  • In August 2020, GlaxoSmithKline plc commenced patient dosing in a phase III clinical study comparing its 5-in-1 meningitis (MenABCWY) vaccine candidate against licenced meningococcal vaccines, Bexsero and Menveo.
  • MenQuadfi was authorised by the European Commission (EC) in November 2020 for active vaccination of people aged 12 months and up against invasive meningococcal illness caused by Neisseria meningitis serogroups A, C, W, and Y.

Report Scope as per Meningococcal Vaccines Industry Analysis

Attribute

Details

Estimated Market Size (2022)

US$ 3.4 Bn

Projected Market Valuation (2032)

US$ 7.7 Bn

Value-based CAGR (2022-2032)

8.6%

Forecast Period

2022-2032

Historical Data Available for

2017-2021

Market Analysis

US$ Bn for Value

Key Regions Covered

North America, Latin America, Europe, South Asia, East Asia, Oceania and Middle East & Africa

Key Countries Covered

The U.S., Canada, Brazil, Mexico, Germany, the U.K., France, Italy, Spain, Russia, Poland, China, Japan, South Korea, India, Thailand, Indonesia, Malaysia, Australia, New Zealand, GCC Countries, Turkey, South Africa and North Africa

Key Market Segments Covered

Product, Age Group, Distribution Channel and Region

Key Companies Profiled

Key Market Segments Covered in Meningococcal Vaccines Industry Research

By Product:

  • Polysaccharide
  • Conjugate

By Age Group:

  • Infants
  • Children
  • Adolescents & young Adults
  • Adults

By Distribution Channel:

  • Pharmacies
  • Community Clinics
  • Public Health Agencies
  • Others (hospital pharmacy, private market etc.)

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa (MEA)

Frequently Asked Questions

The global meningococcal vaccines market is worth US$ 3.4 Bn in 2022 and is set to expand 2.3X over the forecast period.

The meningococcal vaccines market is expected to reach US$ 7.7 Bn by the end of 2032, with sales growing at a 8.6% CAGR.

Expansion of product indications, and increasing pharmacy-based immunization services, are some of the key trends being witnessed in this marketplace.

The U.S., the U.K., China, France, and Japan are expected to drive demand for meningococcal vaccines products.

North America is one of the key markets for meningococcal vaccines, with the U.S. expected to account over 94.0% of the North American market in 2021.

Demand for meningococcal vaccines in Europe is expected to register growth of 8.6% over the next ten years.

Pfizer Inc., Sanofi SA, GSK are the key exporters of meningococcal vaccines market.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Key Market Trends

    3.1. Key Trends Impacting the Market

4. Key Success Factors

    4.1. Disease Epidemiology

    4.2. Pipeline Assessment

    4.3. Parent Market Analysis

5. Market Background

    5.1. Macro-Economic Factors

        5.1.1. Global GDP Growth Outlook

        5.1.2. Global Healthcare GDP Growth Overview

        5.1.3. Shift Towards Value-Based Healthcare Model

        5.1.4. The Most Considered Factor By Companies in Vaccine Pricing

        5.1.5. Global Biotechnology Mergers and Acquisition Overview

    5.2. Forecast Factors - Relevance & Impact

        5.2.1. Global Increase in Healthcare Expenditure

        5.2.2. Expanding Product Indications

        5.2.3. Endemic outbreaks of Meningococcal disease

        5.2.4. Prevalence of Meningococcal disease

        5.2.5. Product Penetration Rate across End Users

        5.2.6. New/Improved Product Launches

    5.3. Market Dynamics

        5.3.1. Drivers

        5.3.2. Restraints

        5.3.3. Opportunity Analysis

6. COVID-19-19 Crisis – Impact Assessment

    6.1. COVID-19 Impact-2021 Market Outlook

    6.2. Short-Mid-Long Term Outlook

7. Global Meningococcal Vaccines Market Demand (in Value or Size in US$ Bn) Analysis 2017–2021 and Forecast, 2022–2032

    7.1. Historical Market Value (US$ Bn) Analysis, 2017–2021

    7.2. Current and Future Market Value (US$ Bn) Projections, 2022–2032

        7.2.1. Y-o-Y Growth Trend Analysis

        7.2.2. Absolute $ Opportunity Analysis

8. Global Meningococcal Vaccines Market Analysis 2017–2021 and Forecast 2022–2032, By Product Type

    8.1. Introduction / Key Findings

    8.2. Historical Market Size (US$ Bn) Analysis By Product Type, 2017–2021

    8.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Product Type, 2022–2032

        8.3.1. Polysaccharide Vaccines

        8.3.2. Conjugate Vaccines

    8.4. Market Attractiveness Analysis By Product Type

9. Global Meningococcal Vaccines Market Analysis 2017–2021 and Forecast 2022–2032, By Age Group

    9.1. Introduction / Key Findings

    9.2. Historical Market Size (US$ Bn), By Age Group, 2017–2021

    9.3. Current and Future Market Size (US$ Bn) and Forecast By Age Group, 2022–2032

        9.3.1. Infants

        9.3.2. Children

        9.3.3. Adolescents & young Adults

        9.3.4. Adults

    9.4. Market Attractiveness Analysis By Age Group

10. Global Meningococcal Vaccines Market Analysis 2017–2021 and Forecast 2022–2032, By Distribution Channel

    10.1. Introduction / Key Findings

    10.2. Historical Market Size (US$ Bn), By Distribution Channel, 2017–2021

    10.3. Current and Future Market Size (US$ Bn) and Forecast By Distribution Channel, 2022–2032

        10.3.1. Pharmacies

        10.3.2. Community Clinics

        10.3.3. Public Health Agencies

        10.3.4. Others (hospital pharmacy, private market etc.)

    10.4. Market Attractiveness Analysis By Distribution Channel

11. Global Meningococcal Vaccines Market Analysis 2017–2021 and Forecast 2022–2032, by Region

    11.1. Introduction

    11.2. Historical Market Size (US$ Bn) Analysis By Region, 2017–2021

    11.3. Current Market Size (US$ Bn) Analysis and Forecast By Region, 2022–2032

        11.3.1. North America

        11.3.2. Latin America

        11.3.3. Europe

        11.3.4. East Asia

        11.3.5. South Asia

        11.3.6. Oceania

        11.3.7. Middle East and Africa (MEA)

    11.4. Market Attractiveness Analysis By Region

12. North America Meningococcal Vaccines Market Analysis 2017–2021 and Forecast 2022–2032

    12.1. Introduction

    12.2. Historical Market Size (US$ Bn) and Trend Analysis By Market Taxonomy, 2017–2021

    12.3. Market Size (US$ Bn) Forecast By Market Taxonomy, 2022–2032

        12.3.1. By Country

            12.3.1.1. U.S.

            12.3.1.2. Canada

        12.3.2. By Product Type

        12.3.3. By Age Group

        12.3.4. By Distribution Channel

    12.4. Market Attractiveness Analysis

        12.4.1. By Country

        12.4.2. By Product Type

        12.4.3. By Age Group

        12.4.4. By Distribution Channel

    12.5. Key Market Participants - Intensity Mapping

    12.6. Drivers and Restraints - Impact Analysis

    12.7. Country Level Analysis & Forecast

        12.7.1. U.S. Meningococcal Vaccines Market Analysis

            12.7.1.1. Introduction

            12.7.1.2. Market Analysis and Forecast by Market Taxonomy

                12.7.1.2.1. By Product Type

                12.7.1.2.2. By Age Group

                12.7.1.2.3. By Distribution Channel

        12.7.2. Canada Meningococcal Vaccines Market Analysis

            12.7.2.1. Introduction

            12.7.2.2. Market Analysis and Forecast by Market Taxonomy

                12.7.2.2.1. By Product Type

                12.7.2.2.2. By Age Group

                12.7.2.2.3. By Distribution Channel

13. Latin America Meningococcal Vaccines Market Analysis 2017–2021 and Forecast 2022–2032

    13.1. Introduction

    13.2. Historical Market Size (US$ Bn) and Trend Analysis By Market Taxonomy, 2017–2021

    13.3. Market Size (US$ Bn) Forecast By Market Taxonomy, 2022–2032

        13.3.1. By Country

            13.3.1.1. Mexico

            13.3.1.2. Brazil

            13.3.1.3. Argentina

            13.3.1.4. Rest of Latin America

        13.3.2. By Product Type

        13.3.3. By Age Group

        13.3.4. By Distribution Channel

    13.4. Market Attractiveness Analysis

        13.4.1. By Country

        13.4.2. By Product Type

        13.4.3. By Age Group

        13.4.4. By Distribution Channel

    13.5. Key Market Participants - Intensity Mapping

    13.6. Drivers and Restraints - Impact Analysis

    13.7. Country Level Analysis & Forecast

        13.7.1. Mexico Meningococcal Vaccines Market Analysis

            13.7.1.1. Introduction

            13.7.1.2. Market Analysis and Forecast by Market Taxonomy

                13.7.1.2.1. By Product Type

                13.7.1.2.2. By Age Group

                13.7.1.2.3. By Distribution Channel

        13.7.2. Brazil Meningococcal Vaccines Market Analysis

            13.7.2.1. Introduction

            13.7.2.2. Market Analysis and Forecast by Market Taxonomy

                13.7.2.2.1. By Product Type

                13.7.2.2.2. By Age Group

                13.7.2.2.3. By Distribution Channel

        13.7.3. Argentina Meningococcal Vaccines Market Analysis

            13.7.3.1. Introduction

            13.7.3.2. Market Analysis and Forecast by Market Taxonomy

                13.7.3.2.1. By Product Type

                13.7.3.2.2. By Age Group

                13.7.3.2.3. By Distribution Channel

        13.7.4. Rest of the Latin America Meningococcal Vaccines Market Analysis

            13.7.4.1. Introduction

            13.7.4.2. Market Analysis and Forecast by Market Taxonomy

                13.7.4.2.1. By Product Type

                13.7.4.2.2. By Age Group

                13.7.4.2.3. By Distribution Channel

14. Europe Meningococcal Vaccines Market Analysis 2017–2021 and Forecast 2022–2032

    14.1. Introduction

    14.2. Historical Market Size (US$ Bn) and Trend Analysis By Market Taxonomy, 2017–2021

    14.3. Market Size (US$ Bn) Forecast By Market Taxonomy, 2022–2032

        14.3.1. By Country

            14.3.1.1. Germany

            14.3.1.2. Italy

            14.3.1.3. France

            14.3.1.4. U.K.

            14.3.1.5. Spain

            14.3.1.6. Poland

            14.3.1.7. Russia

            14.3.1.8. Rest of Europe

        14.3.2. By Product Type

        14.3.3. By Age Group

        14.3.4. By Distribution Channel

    14.4. Market Attractiveness Analysis

        14.4.1. By Country

        14.4.2. By Product Type

        14.4.3. By Age Group

        14.4.4. By Distribution Channel

    14.5. Key Market Participants - Intensity Mapping

    14.6. Drivers and Restraints - Impact Analysis

    14.7. Country Level Analysis & Forecast

        14.7.1. Germany Meningococcal Vaccines Market Analysis

            14.7.1.1. Introduction

            14.7.1.2. Market Analysis and Forecast by Market Taxonomy

                14.7.1.2.1. By Product Type

                14.7.1.2.2. By Age Group

                14.7.1.2.3. By Distribution Channel

        14.7.2. Italy Meningococcal Vaccines Market Analysis

            14.7.2.1. Introduction

            14.7.2.2. Market Analysis and Forecast by Market Taxonomy

                14.7.2.2.1. By Product Type

                14.7.2.2.2. By Age Group

                14.7.2.2.3. By Distribution Channel

        14.7.3. France Meningococcal Vaccines Market Analysis

            14.7.3.1. Introduction

            14.7.3.2. Market Analysis and Forecast by Market Taxonomy

                14.7.3.2.1. By Product Type

                14.7.3.2.2. By Age Group

                14.7.3.2.3. By Distribution Channel

        14.7.4. U.K. Meningococcal Vaccines Market Analysis

            14.7.4.1. Introduction

            14.7.4.2. Market Analysis and Forecast by Market Taxonomy

                14.7.4.2.1. By Product Type

                14.7.4.2.2. By Age Group

                14.7.4.2.3. By Distribution Channel

        14.7.5. Spain Meningococcal Vaccines Market Analysis

            14.7.5.1. Introduction

            14.7.5.2. Market Analysis and Forecast by Market Taxonomy

                14.7.5.2.1. By Product Type

                14.7.5.2.2. By Age Group

                14.7.5.2.3. By Distribution Channel

        14.7.6. Poland Meningococcal Vaccines Market Analysis

            14.7.6.1. Introduction

            14.7.6.2. Market Analysis and Forecast by Market Taxonomy

                14.7.6.2.1. By Product Type

                14.7.6.2.2. By Age Group

                14.7.6.2.3. By Distribution Channel

        14.7.7. Russia Meningococcal Vaccines Market Analysis

            14.7.7.1. Introduction

            14.7.7.2. Market Analysis and Forecast by Market Taxonomy

                14.7.7.2.1. By Product Type

                14.7.7.2.2. By Age Group

                14.7.7.2.3. By Distribution Channel

15. South Asia Meningococcal Vaccines Market Analysis 2017–2021 and Forecast 2022–2032

    15.1. Introduction

    15.2. Historical Market Size (US$ Bn) and Trend Analysis By Market Taxonomy, 2017–2021

    15.3. Market Size (US$ Bn) Forecast By Market Taxonomy, 2022–2032

        15.3.1. By Country

            15.3.1.1. India

            15.3.1.2. Indonesia

            15.3.1.3. Malaysia

            15.3.1.4. Thailand

            15.3.1.5. Rest of South Asia

        15.3.2. By Product Type

        15.3.3. By Age Group

        15.3.4. By Distribution Channel

    15.4. Market Attractiveness Analysis

        15.4.1. By Country

        15.4.2. By Product Type

        15.4.3. By Age Group

        15.4.4. By Distribution Channel

    15.5. Key Market Participants - Intensity Mapping

    15.6. Drivers and Restraints - Impact Analysis

    15.7. Country Level Analysis & Forecast

        15.7.1. India Meningococcal Vaccines Market Analysis

            15.7.1.1. Introduction

            15.7.1.2. Market Analysis and Forecast by Market Taxonomy

                15.7.1.2.1. By Product Type

                15.7.1.2.2. By Age Group

                15.7.1.2.3. By Distribution Channel

        15.7.2. Indonesia Meningococcal Vaccines Market Analysis

            15.7.2.1. Introduction

            15.7.2.2. Market Analysis and Forecast by Market Taxonomy

                15.7.2.2.1. By Product Type

                15.7.2.2.2. By Age Group

                15.7.2.2.3. By Distribution Channel

        15.7.3. Malaysia Meningococcal Vaccines Market Analysis

            15.7.3.1. Introduction

            15.7.3.2. Market Analysis and Forecast by Market Taxonomy

                15.7.3.2.1. By Product Type

                15.7.3.2.2. By Age Group

                15.7.3.2.3. By Distribution Channel

        15.7.4. Thailand Meningococcal Vaccines Market Analysis

            15.7.4.1. Introduction

            15.7.4.2. Market Analysis and Forecast by Market Taxonomy

                15.7.4.2.1. By Product Type

                15.7.4.2.2. By Age Group

                15.7.4.2.3. By Distribution Channel

        15.7.5. Rest of South Asia Meningococcal Vaccines Market Analysis

            15.7.5.1. Introduction

            15.7.5.2. Market Analysis and Forecast by Market Taxonomy

                15.7.5.2.1. By Product Type

                15.7.5.2.2. By Age Group

                15.7.5.2.3. By Distribution Channel

16. East Asia Meningococcal Vaccines Market Analysis 2017–2021 and Forecast 2022–2032

    16.1. Introduction

    16.2. Historical Market Size (US$ Bn) and Trend Analysis By Market Taxonomy, 2017–2021

    16.3. Market Size (US$ Bn) Forecast By Market Taxonomy, 2022–2032

        16.3.1. By Country

            16.3.1.1. China

            16.3.1.2. Japan

            16.3.1.3. South Korea

        16.3.2. By Product Type

        16.3.3. By Age Group

        16.3.4. By Distribution Channel

    16.4. Market Attractiveness Analysis

        16.4.1. By Country

        16.4.2. By Product Type

        16.4.3. By Age Group

        16.4.4. By Distribution Channel

    16.5. Key Market Participants - Intensity Mapping

    16.6. Drivers and Restraints - Impact Analysis

    16.7. Country Level Analysis & Forecast

        16.7.1. China Meningococcal Vaccines Market Analysis

            16.7.1.1. Introduction

            16.7.1.2. Market Analysis and Forecast by Market Taxonomy

                16.7.1.2.1. By Product Type

                16.7.1.2.2. By Age Group

                16.7.1.2.3. By Distribution Channel

        16.7.2. Japan Meningococcal Vaccines Market Analysis

            16.7.2.1. Introduction

            16.7.2.2. Market Analysis and Forecast by Market Taxonomy

                16.7.2.2.1. By Product Type

                16.7.2.2.2. By Age Group

                16.7.2.2.3. By Distribution Channel

        16.7.3. South Korea Meningococcal Vaccines Market Analysis

            16.7.3.1. Introduction

            16.7.3.2. Market Analysis and Forecast by Market Taxonomy

                16.7.3.2.1. By Product Type

                16.7.3.2.2. By Age Group

                16.7.3.2.3. By Distribution Channel

17. Oceania Meningococcal Vaccines Market 2017-2021 and Forecast 2022-2032

    17.1. Introduction

    17.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2017–2021

    17.3. Market Size (US$ Bn) Forecast By Market Taxonomy, 2022–2032

        17.3.1. By Country

            17.3.1.1. Australia

            17.3.1.2. New Zealand

        17.3.2. By Product Type

        17.3.3. By Age Group

        17.3.4. By Distribution Channel

    17.4. Market Attractiveness Analysis

        17.4.1. By Country

        17.4.2. By Product Type

        17.4.3. By Age Group

        17.4.4. By Distribution Channel

    17.5. Key Market Participants - Intensity Mapping

    17.6. Drivers and Restraints - Impact Analysis

    17.7. Country Level Analysis & Forecast

        17.7.1. Australia Meningococcal Vaccines Market Analysis

            17.7.1.1. Introduction

            17.7.1.2. Market Analysis and Forecast by Market Taxonomy

                17.7.1.2.1. By Product Type

                17.7.1.2.2. By Age Group

                17.7.1.2.3. By Distribution Channel

        17.7.2. New Zealand Meningococcal Vaccines Market Analysis

            17.7.2.1. Introduction

            17.7.2.2. Market Analysis and Forecast by Market Taxonomy

                17.7.2.2.1. By Product Type

                17.7.2.2.2. By Age Group

                17.7.2.2.3. By Distribution Channel

18. Middle East and Africa (MEA) Meningococcal Vaccines Market Analysis 2017–2021 and Forecast 2022–2032

    18.1. Introduction

    18.2. Historical Market Size (US$ Bn) and Trend Analysis By Market Taxonomy, 2017–2021

    18.3. Market Size (US$ Bn) Forecast By Market Taxonomy, 2022–2032

        18.3.1. By Country

            18.3.1.1. GCC Countries

            18.3.1.2. South Africa

            18.3.1.3. Rest of Middle East and Africa

        18.3.2. By Product Type

        18.3.3. By Age Group

        18.3.4. By Distribution Channel

    18.4. Market Attractiveness Analysis

        18.4.1. By Country

        18.4.2. By Product Type

        18.4.3. By Age Group

        18.4.4. By Distribution Channel

    18.5. Key Market Participants - Intensity Mapping

    18.6. Drivers and Restraints - Impact Analysis

    18.7. Country Level Analysis & Forecast

        18.7.1. GCC Countries Meningococcal Vaccines Market Analysis

            18.7.1.1. Introduction

            18.7.1.2. Market Analysis and Forecast by Market Taxonomy

                18.7.1.2.1. By Product Type

                18.7.1.2.2. By Age Group

                18.7.1.2.3. By Distribution Channel

        18.7.2. South Africa & North Africa Meningococcal Vaccines Market Analysis

            18.7.2.1. Introduction

            18.7.2.2. Market Analysis and Forecast by Market Taxonomy

                18.7.2.2.1. By Product Type

                18.7.2.2.2. By Age Group

                18.7.2.2.3. By Distribution Channel

        18.7.3. Rest of MEA Meningococcal Vaccines Market Analysis

            18.7.3.1. Introduction

            18.7.3.2. Market Analysis and Forecast by Market Taxonomy

                18.7.3.2.1. By Product Type

                18.7.3.2.2. By Age Group

                18.7.3.2.3. By Distribution Channel

19. Market Structure Analysis

    19.1. Market Analysis by Tier of Companies

    19.2. Market Share Analysis of Top Players

20. Competition Analysis

    20.1. Competition Dashboard

    20.2. Competition Deep Dive

        20.2.1. Pfizer Inc.

            20.2.1.1. Overview

            20.2.1.2. Product Portfolio

            20.2.1.3. Key Financials

            20.2.1.4. Sales Footprint

            20.2.1.5. Strategy Overview

        20.2.2. GlaxoSmithKline plc.

            20.2.2.1. Overview

            20.2.2.2. Product Portfolio

            20.2.2.3. Key Financials

            20.2.2.4. Sales Footprint

            20.2.2.5. Strategy Overview

        20.2.3. Sanofi SA

            20.2.3.1. Overview

            20.2.3.2. Product Portfolio

            20.2.3.3. Key Financials

            20.2.3.4. Sales Footprint

            20.2.3.5. Strategy Overview

        20.2.4. Serum Institute of India

            20.2.4.1. Overview

            20.2.4.2. Product Portfolio

            20.2.4.3. Key Financials

            20.2.4.4. Sales Footprint

            20.2.4.5. Strategy Overview

21. Assumptions and Acronyms Used

22. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 01: Global Meningococcal Vaccine Market Value (US$ Bn) Analysis- and Opportunity Assessment 2017–2032, By Product Type

Table 02: Global Meningococcal Vaccine Market Value (US$ Bn) Analysis and Opportunity Assessment 2017–2032, By Age Group

Table 03: Global Meningococcal Vaccine Market Value (US$ Bn) Analysis- and Opportunity Assessment 2017–2032, By Distribution Channel

Table 04: Global Meningococcal Vaccine Market Value (US$ Bn) Analysis and Opportunity Assessment 2017–2032, By Country

Table 05: North America Meningococcal Vaccine Market Value (US$ Bn) Analysis 2017-2021 and Forecast 2022–2032, By Country

Table 06: North America Meningococcal Vaccine Market Value (US$ Bn) Analysis and Opportunity Assessment 2017–2032, By Product Type

Table 07: North America Meningococcal Vaccine Market Value (US$ Bn) Analysis and Opportunity Assessment 2017–2032, By Age Group

Table 08: North America Meningococcal Vaccine Market Value (US$ Bn) Analysis- and Opportunity Assessment 2017–2032, By Distribution Channel

Table 09: Latin America Meningococcal Vaccine Market Value (US$ Bn) Analysis 2017-2021 and Forecast 2022–2032, By Country

Table 10: Latin America Meningococcal Vaccine Market Value (US$ Bn) Analysis and Opportunity Assessment 2017–2032, By Product Type

Table 11: Latin America Meningococcal Vaccine Market Value (US$ Bn) Analysis and Opportunity Assessment 2017–2032, By Age Group

Table 12: Latin America Meningococcal Vaccine Market Value (US$ Bn) Analysis- and Opportunity Assessment 2017–2032, By Distribution Channel

Table 13: Europe Meningococcal Vaccine Market Value (US$ Bn) Analysis 2017-2021 and Forecast 2022–2032, By Country

Table 14: Europe Meningococcal Vaccine Market Value (US$ Bn) Analysis and Opportunity Assessment 2017–2032, By Product Type

Table 15: Europe Meningococcal Vaccine Market Value (US$ Bn) Analysis and Opportunity Assessment 2017–2032, By Age Group

Table 16: Europe Meningococcal Vaccine Market Value (US$ Bn) Analysis- and Opportunity Assessment 2017–2032, By Distribution Channel

Table 17: South Asia Meningococcal Vaccine Market Value (US$ Bn) Analysis 2017-2021 and Forecast 2022–2032, By Country

Table 18: South Asia Meningococcal Vaccine Market Value (US$ Bn) Analysis and Opportunity Assessment 2017–2032, By Product Type

Table 19: South Asia Meningococcal Vaccine Market Value (US$ Bn) Analysis and Opportunity Assessment 2017–2032, By Age Group

Table 20: South Asia Meningococcal Vaccine Market Value (US$ Bn) Analysis- and Opportunity Assessment 2017–2032, By Distribution Channel

Table 21: East Asia Meningococcal Vaccine Market Value (US$ Bn) Analysis 2017-2021 and Forecast 2022–2032, By Country

Table 22: East Asia Meningococcal Vaccine Market Value (US$ Bn) Analysis and Opportunity Assessment 2017–2032, By Product Type

Table 23: East Asia Meningococcal Vaccine Market Value (US$ Bn) Analysis and Opportunity Assessment 2017–2032, By Age Group

Table 24: East Asia Meningococcal Vaccine Market Value (US$ Bn) Analysis- and Opportunity Assessment 2017–2032, By Distribution Channel

Table 25: Oceania Meningococcal Vaccine Market Value (US$ Bn) Analysis 2017-2021 and Forecast 2022–2032, By Country

Table 26: Oceania Meningococcal Vaccine Market Value (US$ Bn) Analysis and Opportunity Assessment 2017–2032, By Product Type

Table 27: Oceania Meningococcal Vaccine Market Value (US$ Bn) Analysis and Opportunity Assessment 2017–2032, By Age Group

Table 28: Oceania Meningococcal Vaccine Market Value (US$ Bn) Analysis- and Opportunity Assessment 2017–2032, By Distribution Channel

Table 29: MEA Meningococcal Vaccine Market Value (US$ Bn) Analysis 2017-2021 and Forecast 2022–2032, By Country

Table 30: MEA Meningococcal Vaccine Market Value (US$ Bn) Analysis and Opportunity Assessment 2017–2032, By Product Type

Table 31: MEA Meningococcal Vaccine Market Value (US$ Bn) Analysis and Opportunity Assessment 2017–2032, By Age Group

Table 32: MEA Meningococcal Vaccine Market Value (US$ Bn) Analysis- and Opportunity Assessment 2017–2032, By Distribution Channel

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 01: Global Meningococcal Vaccine Market Value Analysis (US$ Bn), 2017-2021

Figure 02: Global Meningococcal Vaccine Market Value Forecast (US$ Bn), 2022–2032

Figure 03: Global Meningococcal Vaccine Market Absolute $ Opportunity, 2022 - 2032

Figure 04: Global Meningococcal Vaccine Market Share Analysis (%), By Product Type, 2022 & 2032

Figure 05: Global Meningococcal Vaccine Market Y-o-Y Analysis (%), By Product Type, 2022–2032

Figure 06: Global Meningococcal Vaccine Market Attractiveness Analysis by Product Type, 2022–2032

Figure 07: Global Meningococcal Vaccine Market Share Analysis (%), By Age Group, 2022 & 2032

Figure 08: Global Meningococcal Vaccine Market Y-o-Y Analysis (%), By Age Group, 2022–2032

Figure 09: Global Meningococcal Vaccine Market Attractiveness Analysis By Age Group, 2022–2032

Figure 10: Global Meningococcal Vaccine Market Share Analysis (%), By Distribution Channel, 2022 & 2032

Figure 11: Global Meningococcal Vaccine Market Y-o-Y Analysis (%), By Distribution Channel, 2022–2032

Figure 12: Global Meningococcal Vaccine Market Attractiveness Analysis By Distribution Channel, 2022–2032

Figure 13: Global Meningococcal Vaccine Market Share Analysis (%), By Region , 2022 & 2032

Figure 14: Global Meningococcal Vaccine Market Y-o-Y Analysis (%), By Country, 2022–2032

Figure 15: Global Meningococcal Vaccine Market Attractiveness Analysis by Region, 2022–2032

Figure 16: North America Meningococcal Vaccine Market Value Share, By Product Type, 2022 (E)

Figure 17: North America Meningococcal Vaccine Market Value Share, By Age Group, 2022 (E)

Figure 18: North America Meningococcal Vaccine Market Value Share, By Distribution Channel, 2022 (E)

Figure 19: North America Meningococcal Vaccine Market Value Share, By Country, 2022 (E)

Figure 20: North America Meningococcal Vaccine Market Value Analysis (US$ Bn), 2017-2021

Figure 21: North America Meningococcal Vaccine Market Value Forecast (US$ Bn), 2022–2032

Figure 22: North America Meningococcal Vaccine Market Attractiveness Analysis by Product Type, 2022–2032

Figure 23: North America Meningococcal Vaccine Market Attractiveness Analysis by Age Group, 2022–2032

Figure 24: North America Meningococcal Vaccine Market Attractiveness Analysis By Distribution Channel, 2022–2032

Figure 25: North America Meningococcal Vaccine Market Attractiveness Analysis By Country, 2022–2032

Figure 26: U.S. Market Value Proportion Analysis, 2022

Figure 27: Global Vs. U.S. Growth Comparison

Figure 28: U.S. Meningococcal Vaccine Market Share Analysis (%) By Product Type, 2022 & 2032

Figure 29: U.S. Meningococcal Vaccine Market Share Analysis (%) by Age Group, 2022 & 2032

Figure 30: U.S. Meningococcal Vaccine Market Share Analysis (%) by Distribution Channel, 2022 & 2032

Figure 31: Canada Market Value Proportion Analysis, 2022

Figure 32: Global Vs. Canada Growth Comparison

Figure 33: Canada Meningococcal Vaccine Market Share Analysis (%) By Product Type, 2022 & 2032

Figure 34: Canada Meningococcal Vaccine Market Share Analysis (%) by Age Group, 2022 & 2032

Figure 35: Canada Meningococcal Vaccine Market Share Analysis (%) by Distribution Channel, 2022 & 2032

Figure 36: Latin America Meningococcal Vaccine Market Value Share, By Product Type, 2022 (E)

Figure 37: Latin America Meningococcal Vaccine Market Value Share, By Age Group, 2022 (E)

Figure 38: Latin America Meningococcal Vaccine Market Value Share, By Distribution Channel, 2022 (E)

Figure 39: Latin America Meningococcal Vaccine Market Value Share, By Country, 2022 (E)

Figure 40: Latin America Meningococcal Vaccine Market Value Analysis (US$ Bn), 2017-2021

Figure 41: Latin America Meningococcal Vaccine Market Value Forecast (US$ Bn), 2022–2032

Figure 42: Latin America Meningococcal Vaccine Market Attractiveness Analysis by Product Type, 2022–2032

Figure 43: Latin America Meningococcal Vaccine Market Attractiveness Analysis by Age Group, 2022–2032

Figure 44: Latin America Meningococcal Vaccine Market Attractiveness Analysis By Distribution Channel, 2022–2032

Figure 45: Latin America Meningococcal Vaccine Market Attractiveness Analysis By Country, 2022–2032

Figure 46: Brazil Market Value Proportion Analysis, 2022

Figure 47: Global Vs. Brazil Growth Comparison

Figure 48: Brazil Meningococcal Vaccine Market Share Analysis (%) By Product Type, 2022 & 2032

Figure 49: Brazil Meningococcal Vaccine Market Share Analysis (%) by Age Group, 2022 & 2032

Figure 50: Brazil Meningococcal Vaccine Market Share Analysis (%) by Distribution Channel, 2022 & 2032

Figure 51: Mexico Market Value Proportion Analysis, 2022

Figure 52: Global Vs. Mexico Growth Comparison

Figure 53: Mexico Meningococcal Vaccine Market Share Analysis (%) By Product Type, 2022 & 2032

Figure 54: Mexico Meningococcal Vaccine Market Share Analysis (%) by Age Group, 2022 & 2032

Figure 55: Mexico Meningococcal Vaccine Market Share Analysis (%) by Distribution Channel, 2022 & 2032

Figure 56: Europe Meningococcal Vaccine Market Value Share, By Product Type, 2022 (E)

Figure 57: Europe Meningococcal Vaccine Market Value Share, By Age Group, 2022 (E)

Figure 58: Europe Meningococcal Vaccine Market Value Share, By Distribution Channel, 2022 (E)

Figure 59: Europe Meningococcal Vaccine Market Value Share, By Country, 2022 (E)

Figure 60: Europe Meningococcal Vaccine Market Value Analysis (US$ Bn), 2017-2021

Figure 61: Europe Meningococcal Vaccine Market Value Forecast (US$ Bn), 2022–2032

Figure 62: Europe Meningococcal Vaccine Market Attractiveness Analysis by Product Type, 2022–2032

Figure 63: Europe Meningococcal Vaccine Market Attractiveness Analysis by Age Group, 2022–2032

Figure 64: Europe Meningococcal Vaccine Market Attractiveness Analysis By Distribution Channel, 2022–2032

Figure 65: Europe Meningococcal Vaccine Market Attractiveness Analysis By Country, 2022–2032

Figure 66: U.K. Market Value Proportion Analysis, 2022

Figure 67: Global Vs. U.K. Growth Comparison

Figure 68: U.K. Meningococcal Vaccine Market Share Analysis (%) By Product Type, 2022 & 2032

Figure 69: U.K. Meningococcal Vaccine Market Share Analysis (%) by Age Group, 2022 & 2032

Figure 70: U.K. Meningococcal Vaccine Market Share Analysis (%) by Distribution Channel, 2022 & 2032

Figure 71: France Market Value Proportion Analysis, 2022

Figure 72: Global Vs. France Growth Comparison

Figure 73: France Meningococcal Vaccine Market Share Analysis (%) By Product Type, 2022 & 2032

Figure 74: France Meningococcal Vaccine Market Share Analysis (%) by Age Group, 2022 & 2032

Figure 75: France Meningococcal Vaccine Market Share Analysis (%) by Distribution Channel, 2022 & 2032

Figure 76: Germany Market Value Proportion Analysis, 2022

Figure 77: Global Vs. Germany Growth Comparison

Figure 78: Germany Meningococcal Vaccine Market Share Analysis (%) By Product Type, 2022 & 2032

Figure 79: Germany Meningococcal Vaccine Market Share Analysis (%) by Age Group, 2022 & 2032

Figure 80: Germany Meningococcal Vaccine Market Share Analysis (%) by Distribution Channel, 2022 & 2032

Figure 81: Italy Market Value Proportion Analysis, 2022

Figure 82: Global Vs. Italy Growth Comparison

Figure 83: Italy Meningococcal Vaccine Market Share Analysis (%) By Product Type, 2022 & 2032

Figure 84: Italy Meningococcal Vaccine Market Share Analysis (%) by Age Group, 2022 & 2032

Figure 85: Italy Meningococcal Vaccine Market Share Analysis (%) by Distribution Channel, 2022 & 2032

Figure 86: Spain Market Value Proportion Analysis, 2022

Figure 87: Global Vs. Spain Growth Comparison

Figure 88: Spain Meningococcal Vaccine Market Share Analysis (%) By Product Type, 2022 & 2032

Figure 89: Spain Meningococcal Vaccine Market Share Analysis (%) by Age Group, 2022 & 2032

Figure 90: Spain Meningococcal Vaccine Market Share Analysis (%) by Distribution Channel, 2022 & 2032

Figure 91: Russia Market Value Proportion Analysis, 2022

Figure 92: Global Vs. Russia Growth Comparison

Figure 93: Russia Meningococcal Vaccine Market Share Analysis (%) By Product Type, 2022 & 2032

Figure 94: Russia Meningococcal Vaccine Market Share Analysis (%) by Age Group, 2022 & 2032

Figure 95: Russia Meningococcal Vaccine Market Share Analysis (%) by Distribution Channel, 2022 & 2032

Figure 96: Poland Market Value Proportion Analysis, 2022

Figure 97: Global Vs. Poland Growth Comparison

Figure 98: Poland Meningococcal Vaccine Market Share Analysis (%) By Product Type, 2022 & 2032

Figure 99: Poland Meningococcal Vaccine Market Share Analysis (%) by Age Group, 2022 & 2032

Figure 100: Poland Meningococcal Vaccine Market Share Analysis (%) by Distribution Channel, 2022 & 2032

Figure 101: South Asia Meningococcal Vaccine Market Value Share, By Product Type, 2022 (E)

Figure 102: South Asia Meningococcal Vaccine Market Value Share, By Age Group, 2022 (E)

Figure 103: South Asia Meningococcal Vaccine Market Value Share, By Distribution Channel, 2022 (E)

Figure 104: South Asia Meningococcal Vaccine Market Value Share, By Country, 2022 (E)

Figure 105: South Asia Meningococcal Vaccine Market Value Analysis (US$ Bn), 2017-2021

Figure 106: South Asia Meningococcal Vaccine Market Value Forecast (US$ Bn), 2022–2032

Figure 107: South Asia Meningococcal Vaccine Market Attractiveness Analysis by Product Type, 2022–2032

Figure 108: South Asia Meningococcal Vaccine Market Attractiveness Analysis by Age Group, 2022–2032

Figure 109: South Asia Meningococcal Vaccine Market Attractiveness Analysis By Distribution Channel, 2022–2032

Figure 110: South Asia Meningococcal Vaccine Market Attractiveness Analysis By Country, 2022–2032

Figure 111: India Market Value Proportion Analysis, 2022

Figure 112: Global Vs. India Growth Comparison

Figure 113: India Meningococcal Vaccine Market Share Analysis (%) By Product Type, 2022 & 2032

Figure 114: India Meningococcal Vaccine Market Share Analysis (%) by Age Group, 2022 & 2032

Figure 115: India Meningococcal Vaccine Market Share Analysis (%) by Distribution Channel, 2022 & 2032

Figure 116: Thailand Market Value Proportion Analysis, 2022

Figure 117: Global Vs. Thailand Growth Comparison

Figure 118: Thailand Meningococcal Vaccine Market Share Analysis (%) By Product Type, 2022 & 2032

Figure 119: Thailand Meningococcal Vaccine Market Share Analysis (%) by Age Group, 2022 & 2032

Figure 120: Thailand Meningococcal Vaccine Market Share Analysis (%) by Distribution Channel, 2022 & 2032

Figure 121: Malaysia Market Value Proportion Analysis, 2022

Figure 122: Global Vs. Malaysia Growth Comparison

Figure 123: Malaysia Meningococcal Vaccine Market Share Analysis (%) By Product Type, 2022 & 2032

Figure 124: Malaysia Meningococcal Vaccine Market Share Analysis (%) by Age Group, 2022 & 2032

Figure 125: Malaysia Meningococcal Vaccine Market Share Analysis (%) by Distribution Channel, 2022 & 2032

Figure 126: Indonesia Market Value Proportion Analysis, 2022

Figure 127: Global Vs. Indonesia Growth Comparison

Figure 128: Indonesia Meningococcal Vaccine Market Share Analysis (%) By Product Type, 2022 & 2032

Figure 129: Indonesia Meningococcal Vaccine Market Share Analysis (%) by Age Group, 2022 & 2032

Figure 130: Indonesia Meningococcal Vaccine Market Share Analysis (%) by Distribution Channel, 2022 & 2032

Figure 131: East Asia Meningococcal Vaccine Market Value Share, By Product Type, 2022 (E)

Figure 132: East Asia Meningococcal Vaccine Market Value Share, By Age Group, 2022 (E)

Figure 133: East Asia Meningococcal Vaccine Market Value Share, By Distribution Channel, 2022 (E)

Figure 134: East Asia Meningococcal Vaccine Market Value Share, By Country, 2022 (E)

Figure 135: East Asia Meningococcal Vaccine Market Value Analysis (US$ Bn), 2017-2021

Figure 136: East Asia Meningococcal Vaccine Market Value Forecast (US$ Bn), 2022–2032

Figure 137: East Asia Meningococcal Vaccine Market Attractiveness Analysis by Product Type, 2022–2032

Figure 138: East Asia Meningococcal Vaccine Market Attractiveness Analysis by Age Group, 2022–2032

Figure 139: East Asia Meningococcal Vaccine Market Attractiveness Analysis By Distribution Channel, 2022–2032

Figure 140: East Asia Meningococcal Vaccine Market Attractiveness Analysis By Country, 2022–2032

Figure 141: China Market Value Proportion Analysis, 2022

Figure 142: Global Vs. China Growth Comparison

Figure 143: China Meningococcal Vaccine Market Share Analysis (%) By Product Type, 2022 & 2032

Figure 144: China Meningococcal Vaccine Market Share Analysis (%) by Age Group, 2022 & 2032

Figure 145: China Meningococcal Vaccine Market Share Analysis (%) by Distribution Channel, 2022 & 2032

Figure 146: Japan Market Value Proportion Analysis, 2022

Figure 147: Global Vs. Japan Growth Comparison

Figure 148: Japan Meningococcal Vaccine Market Share Analysis (%) By Product Type, 2022 & 2032

Figure 149: Japan Meningococcal Vaccine Market Share Analysis (%) by Age Group, 2022 & 2032

Figure 150: Japan Meningococcal Vaccine Market Share Analysis (%) by Distribution Channel, 2022 & 2032

Figure 151: South Korea Market Value Proportion Analysis, 2022

Figure 152: Global Vs. South Korea Growth Comparison

Figure 153: South Korea Meningococcal Vaccine Market Share Analysis (%) By Product Type, 2022 & 2032

Figure 154: South Korea Meningococcal Vaccine Market Share Analysis (%) by Age Group, 2022 & 2032

Figure 155: South Korea Meningococcal Vaccine Market Share Analysis (%) by Distribution Channel, 2022 & 2032

Figure 156: Oceania Meningococcal Vaccine Market Value Share, By Product Type, 2022 (E)

Figure 157: Oceania Meningococcal Vaccine Market Value Share, By Age Group, 2022 (E)

Figure 158: Oceania Meningococcal Vaccine Market Value Share, By Distribution Channel, 2022 (E)

Figure 159: Oceania Meningococcal Vaccine Market Value Share, By Country, 2022 (E)

Figure 160: Oceania Meningococcal Vaccine Market Value Analysis (US$ Bn), 2017-2021

Figure 161: Oceania Meningococcal Vaccine Market Value Forecast (US$ Bn), 2022–2032

Figure 162: Oceania Meningococcal Vaccine Market Attractiveness Analysis by Product Type, 2022–2032

Figure 163: Oceania Meningococcal Vaccine Market Attractiveness Analysis by Age Group, 2022–2032

Figure 164: Oceania Meningococcal Vaccine Market Attractiveness Analysis By Distribution Channel, 2022–2032

Figure 165: Oceania Meningococcal Vaccine Market Attractiveness Analysis By Country, 2022–2032

Figure 166: Australia Market Value Proportion Analysis, 2022

Figure 167: Global Vs. Australia Growth Comparison

Figure 168: Australia Meningococcal Vaccine Market Share Analysis (%) By Product Type, 2022 & 2032

Figure 169: Australia Meningococcal Vaccine Market Share Analysis (%) by Age Group, 2022 & 2032

Figure 170: Australia Meningococcal Vaccine Market Share Analysis (%) by Distribution Channel, 2022 & 2032

Figure 171: New Zealand Market Value Proportion Analysis, 2022

Figure 172: Global Vs. New Zealand Growth Comparison

Figure 173: New Zealand Meningococcal Vaccine Market Share Analysis (%) By Product Type, 2022 & 2032

Figure 174: New Zealand Meningococcal Vaccine Market Share Analysis (%) by Age Group, 2022 & 2032

Figure 175: New Zealand Meningococcal Vaccine Market Share Analysis (%) by Distribution Channel, 2022 & 2032

Figure 176: MEA Meningococcal Vaccine Market Value Share, By Product Type, 2022 (E)

Figure 177: MEA Meningococcal Vaccine Market Value Share, By Age Group, 2022 (E)

Figure 178: MEA Meningococcal Vaccine Market Value Share, By Distribution Channel, 2022 (E)

Figure 179: MEA Meningococcal Vaccine Market Value Share, By Country, 2022 (E)

Figure 180: MEA Meningococcal Vaccine Market Value Analysis (US$ Bn), 2017-2021

Figure 181: MEA Meningococcal Vaccine Market Value Forecast (US$ Bn), 2022–2032

Figure 182: MEA Meningococcal Vaccine Market Attractiveness Analysis by Product Type, 2022–2032

Figure 183: MEA Meningococcal Vaccine Market Attractiveness Analysis by Age Group, 2022–2032

Figure 184: MEA Meningococcal Vaccine Market Attractiveness Analysis By Distribution Channel, 2022–2032

Figure 185: MEA Meningococcal Vaccine Market Attractiveness Analysis By Country, 2022–2032

Figure 186: Turkey Market Value Proportion Analysis, 2022

Figure 187: Global Vs. Turkey Growth Comparison

Figure 188: Turkey Meningococcal Vaccine Market Share Analysis (%) By Product Type, 2022 & 2032

Figure 189: Turkey Meningococcal Vaccine Market Share Analysis (%) by Age Group, 2022 & 2032

Figure 190: Turkey Meningococcal Vaccine Market Share Analysis (%) by Distribution Channel, 2022 & 2032

Figure 191: GCC Countries Market Value Proportion Analysis, 2022

Figure 192: Global Vs. GCC Countries Growth Comparison

Figure 193: GCC Countries Meningococcal Vaccine Market Share Analysis (%) By Product Type, 2022 & 2032

Figure 194: GCC Countries Meningococcal Vaccine Market Share Analysis (%) by Age Group, 2022 & 2032

Figure 195: GCC Countries Meningococcal Vaccine Market Share Analysis (%) by Distribution Channel, 2022 & 2032

Figure 196: North Africa Market Value Proportion Analysis, 2022

Figure 197: Global Vs. North Africa Growth Comparison

Figure 198: North Africa Meningococcal Vaccine Market Share Analysis (%) By Product Type, 2022 & 2032

Figure 199: North Africa Meningococcal Vaccine Market Share Analysis (%) by Age Group, 2022 & 2032

Figure 200: North Africa Meningococcal Vaccine Market Share Analysis (%) by Distribution Channel, 2022 & 2032

Figure 201: South Africa Market Value Proportion Analysis, 2022

Figure 202: Global Vs. South Africa Growth Comparison

Figure 203: South Africa Meningococcal Vaccine Market Share Analysis (%) By Product Type, 2022 & 2032

Figure 204: South Africa Meningococcal Vaccine Market Share Analysis (%) by Age Group, 2022 & 2032

Figure 205: South Africa Meningococcal Vaccine Market Share Analysis (%) by Distribution Channel, 2022 & 2032

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Vaccines Market

Published : February 2022

Healthcare

Dengue Vaccines Market

Published : April 2021

Healthcare

Anti-Infective Vaccines Market

Published : April 2016

Healthcare

Veterinary Vaccines Market

Published : February 2022

Google translate

Meningococcal Vaccines Market